中国支付BioNTech 8500万美元的COVID疫苗许可费
BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group to exclusively develop and commercialise Covid-19 vaccine products developed using BioNTech’s mRNA technology in mainland China, Hong Kong, Macau and Taiwan.
In return it agreed to pay up to $85m in licensing fees and invest $50m for a stake in the German firm.
|